Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-16	₩3,625.00	-6.57%	241,230
26-07-15	₩3,880.00	+8.08%	242,777
26-07-14	₩3,590.00	-8.77%	421,874
26-07-13	₩3,935.00	-7.63%	382,836
26-07-10	₩4,260.00	+11.23%	498,274

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-07-16			5-day change	1st Jan Change
3,625.00 ^KRW	-6.57%		-14.91%	-47.31%

Apr. 13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
Apr. 02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

Market Cap	164B 110M 96.25M 88.81M 81.86M 154M 10.61B 158M 1.06B 418M 5.19B 414M 405M 17.88B	P/E 2024	-4.17x	P/E 2025	-33.5x
Enterprise Value	146B 98.12M 85.75M 79.13M 72.94M 137M 9.45B 141M 946M 372M 4.63B 368M 360M 15.93B	EV / Sales 2024	1.31x	EV / Sales 2025	8.97x
Free-Float	82.79%	Yield 2024 *	-	Yield 2025	-

Apr. 13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
Apr. 02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
Mar. 12	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
25-09-21	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
25-08-20	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
25-07-10	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
25-04-27	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
25-04-23	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
25-04-23	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
25-04-23	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
24-07-18	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24-07-16	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24-01-24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI

1 day	-6.57%
1 week	-14.91%
Current month	-6.09%
1 month	-31.21%
3 months	-48.87%
6 months	-48.21%
Current year	-47.31%

Genome & Company Stock

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

Valuation: Genome & Company

Chart: Genome & Company

Latest news : Genome & Company

Quotes and Performance

Course Extremes

Managers and Directors: Genome & Company

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	3,455	4,375
1 month	3,435	4,990
Current year	3,435	10,180
1 year	2,440	10,180
3 years	2,170	10,180
5 years	2,170	28,800
10 years	2,170	47,500

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	2015-09-23
Ji-Soo Bae CEO	Chief Executive Officer	55	2015-09-23

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	2015-09-23
Han-Su Park BRD	Director/Board Member	53	2015-09-23
Yu-Seok Hong BRD	Director/Board Member	62	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/9/25	Jin-kyung Seo	Free		10,000	0.0322%
5/9/25	Byung-Gyu Park	Free	Public Communications Manager	50,000	0.1608%
5/9/25	Ji-Soo Bae	Don	Founder	90,000	0.2895%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	-6.57%	-14.91%	+19.24%	-48.94%	110M
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+593.85%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+60.25%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.01%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.38%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+115.55%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+19.16%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-30.79%	13.02B
ABIVAX	-0.08%	-3.01%	+1,282.83%	+635.80%	11.76B
Average	-0.49%	-1.46%	+203.36%	+152.36%	20.63B
Weighted average by Cap.	+0.24%	+0.35%	+174.48%	+186.01%

	2024	2025
Net sales	27.74B 18.66M 16.31M 15.05M 13.87M 26.14M 1.8B 26.72M 180M 70.73M 880M 70.07M 68.53M 3.03B	24.59B 16.53M 14.45M 13.33M 12.29M 23.16M 1.59B 23.68M 159M 62.68M 780M 62.1M 60.73M 2.68B
Net income	-20.11B -13.53M -11.82M -10.91M -10.05M -18.95M -1.3B -19.37M -130M -51.28M -638M -50.8M -49.68M -2.2B	-6.43B -4.32M -3.78M -3.49M -3.21M -6.06M -416M -6.19M -41.67M -16.39M -204M -16.23M -15.88M -702M
Net Debt	-48.91B -32.89M -28.74M -26.52M -24.45M -46.08M -3.17B -47.1M -317M -125M -1.55B -124M -121M -5.34B	-17.86B -12.01M -10.5M -9.69M -8.93M -16.83M -1.16B -17.2M -116M -45.54M -567M -45.11M -44.12M -1.95B